At the news
? BEARISHIMPACT 6/10 424B5 filed Jun 25, 2026 at 16:24 ET
Taysha Gene Therapies is raising approximately $187.4 million ($215.6 million if underwriters' option is exercised) through the sale of 32.5M shares of common stock and pre-funded warrants at $6.00 per share, representing a 13.6% discount to the $6.94 prior closing price. Net proceeds combined with existing $276.6M cash will fund TSHA-102 BLA preparation/commercial launch and pipeline development, extending runway into H2 2028. The offering creates immediate 79% dilution ($4.75/share) for new investors.
- Offering of 32,500,001 shares of common stock at $6.00/share, a 13.6% discount to the prior close of $6.94
- Pre-funded warrants for up to 833,333 additional shares at $5.999 per warrant (exercise price $0.001)
- Net proceeds estimated at $187.4M (or $215.6M with underwriter option exercise)
- Immediate dilution of $4.75 per share for new investors (79% of offering price)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access